The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Discussing the concept of a cure in multiple myeloma: is the term over-promising?
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the concept of a cure in multiple myeloma, noting that while curing every patient with myeloma is still far away, a significant fraction of patients may become disease-free with current and emerging treatments. Dr Schjesvold believes that using the word “cure” is not over-promising if put into the right context, and that it is a relevant and hopeful term to discuss with patients. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
